Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00038779 · ClinicalTrials.gov registry record · NA
Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States
A NA study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT00038779: Clinical Trial NA study, sponsored by M.D. Anderson Cancer Center.
NCT00038779 is a NA study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 7 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00038779, a NA study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to assess early treatment failure within 100 days and to assess the effect of this regimen on engraftment, GVHD, immune recovery, relapse of malignancy and survival.
Interventions
- PROCEDURE Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 1996-08-14 |
| Est. Completion | 2004-09-20 |
| Phase | NA |
Why NCT00038779 stopped before completion
NCT00038779 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation is the first listed.
NCT00038779 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00038779 about?
NCT00038779 is a clinical study titled "Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States". The purpose of this study is to assess early treatment failure within 100 days and to assess the effect of this regimen on engraftment, GVHD, immune recovery, relapse of malignancy and survival.
What is the current status of trial NCT00038779?
This trial is currently terminated. It is a NA study. The enrollment target is 7 participants. The study started on 1996-08-14. Estimated completion is 2004-09-20.
What interventions are being tested in trial NCT00038779?
The interventions under investigation include: Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00038779?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00038779's enrollment target sits among peer trials
7 1982nd of 2000 higher than 18 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI